Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

[1]  F. Labrie,et al.  647: Relationship Between the PSA Value at First Visit and PSA Progression and Prostate Cancer Diagnosis at Annual Follow-Up Visits , 2004 .

[2]  M. Roobol,et al.  The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[3]  M. Roobol,et al.  Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) , 2003, BJU international.

[4]  Kazuto Ito,et al.  Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less , 2003, The Prostate.

[5]  Kazuto Ito,et al.  Natural history of PSA increase with and without prostate cancer. , 2003, Urology.

[6]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[7]  J. Hugosson,et al.  Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. , 2003, The Journal of urology.

[8]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[9]  T. H. van der Kwast,et al.  Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. , 2001, Urology.

[10]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[11]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[12]  J. Habbema,et al.  Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam) , 1999, International journal of cancer.

[13]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[14]  D. Chan,et al.  Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. , 1997, JAMA.

[15]  E. Metter,et al.  Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. , 1995, Urology.

[16]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.